Athira pharma settles research misconduct charges for $4 million
By 
Rebecca Trager2025-01-14T12:30:00
Deal with US Department of Justice resolves allegations against former chief executive
US biopharmaceutical company Athira Pharma has agreed to pay more than $4 million (£3.3 million) to resolve allegations that it violated the False Claims Act (FCA) by failing to report allegations of research misconduct by its former chief executive, Leen Kawas.